Aetna Medicaid Deepens Commitment to Ending Hunger with $500,000 Investment in Community Food Organizations Nationwide In a powerful demonstration of its ongoing dedication to community health and well-being, Aetna Medicaid—part of CVS Health® (NYSE: CVS)—has announced a significant $500,000 donation…
FDA Grants Priority Review to AstraZeneca’s Baxdrostat for Hard-to-Control Hypertension—A Potential First-in-Class Therapy In a significant milestone for cardiovascular innovation, the U.S. Food and Drug Administration (FDA) has accepted AstraZeneca’s New Drug Application (NDA) for baxdrostat under Priority Review, signaling…
SCRI Unveils Groundbreaking Blood Cancer and Blood Disorder Research Through 100 Abstracts at 2025 ASH Annual Meeting In a historic showing that underscores its growing prominence in hematology research, the Sarah Cannon Research Institute (SCRI) will present 100 abstracts and…
AdvanCell Launches Pivotal Phase 2 Expansion Trial of ADVC001, a First-in-Class Targeted Alpha Therapy for Metastatic Prostate Cancer AdvanCell, a clinical-stage radiopharmaceutical company at the forefront of developing next-generation targeted alpha therapies (TATs) for oncology, has announced the initiation of…
Samsung Bioepis Launches Denosumab Biosimilars OBODENCE™ and XBRYK™ in Europe to Improve Access and Patient Outcomes Samsung Bioepis Co., Ltd., a global biopharmaceutical company recognized for its innovative work in developing biosimilars across multiple therapeutic areas, today announced the commercial…
Janux Therapeutics Reports Encouraging Interim Phase 1 Data for JANX007 in mCRPC, Highlighting Strong Efficacy and Manageable Safety Profile Janux Therapeutics, Inc. a clinical-stage biopharmaceutical company pioneering novel immunotherapies through its proprietary platforms—Tumor Activated T Cell Engager (TRACTr), Tumor Activated…
AltPep Corporation Presents New Preclinical Data Demonstrating SOBIN-AD Peptide Improves Cognition in Early and Symptomatic Alzheimer’s Disease Models at CTAD 2025 AltPep Corporation, a privately held biotechnology company dedicated to developing early disease-modifying therapies and innovative detection tools for amyloid-related…
Vistagen Appoints Nick Tressler as Chief Financial Officer, Strengthening Leadership Team Amid Growth and Clinical Milestones Vistagen Therapeutics, Inc. a late clinical-stage biopharmaceutical company focused on pioneering neuroscience innovations through nose-to-brain neurocircuitry, today announced the appointment of Nick Tressler as…
Mirum Pharmaceuticals Enrolls First Participant in BLOOM Phase 2 Study Evaluating MRM-3379 for Fragile X Syndrome Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and delivering innovative therapies for rare diseases, announced today a key milestone in its development…
Circle Pharma Appoints Anne E. Borgman, M.D., as Chief Medical Officer, Strengthening Leadership Team to Advance Next-Generation Macrocycle Oncology Pipeline Circle Pharma, Inc., a clinical-stage biopharmaceutical company advancing a new class of targeted macrocycle therapeutics designed to address some of…
Celltrion Receives Health Canada Approval for Eydenzelt®, a Biosimilar Referencing Eylea® Celltrion, Inc. has announced a major regulatory milestone with the approval of Eydenzelt® by Health Canada. The newly approved biosimilar references Eylea® (aflibercept 2mg) and will be available to…
Otsuka Announces FDA Accelerated Approval of VOYXACT® for Proteinuria Reduction in Adults with Primary IgA Nephropathy Otsuka Pharmaceutical Development & Commercialization, Inc., together with Otsuka Pharmaceutical Co., Ltd., announced that the U.S. Food and Drug Administration (FDA) has granted accelerated…
